Clinical trial Recruiting at 1 site Phase 1 Interventional Ages 18 to 65

First-in-human assessment of S-1117 in healthy volunteers

Official title: A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Single and Multiple Ascending Dose Trial of S-1117 in Healthy Volunteers

Run by Seismic Therapeutic AU Pty Ltd · NCT06828393 · Data updated 2026-11-12

This study is testing a new drug called S-1117 in healthy adults to see how safe it is and how it works in the body.

More Healthy Volunteer Study trials

Quick facts

PhasePhase 1
Study typeInterventional
Ages18 Years to 65 Years
SexAll
Enrollment96 (estimated)
SponsorSeismic Therapeutic AU Pty Ltd
Industry-sponsored
Locations1 site (Adelaide, South Australia)
StatusRecruiting
StartedMarch 2025
Main results expectedMarch 2026
Study endsMarch 2026
Registry record updatedMarch 12, 2025
Trial IDNCT06828393 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are healthy adults aged 18 to 65 with a BMI between 18 and 32 kg/m2.

Probably not a fit

Patients with a history of severe allergies, immunodeficiency disorders, or certain medical conditions may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the safety, tolerability, pharmacokinetics, and pharmacodynamics of S-1117 in healthy adult participants. It is a randomized, placebo-controlled, double-blind trial conducted in two parts: the first part involves single ascending doses, while the second part focuses on multiple ascending doses. The goal is to gather essential data on how S-1117 behaves in the human body and its potential effects.

Why it matters

Potential benefit: If successful, this study could provide critical safety and efficacy data that may lead to the development of new therapeutic options.

How similar studies have gone: Other first-in-human studies have shown success in assessing new compounds, making this approach a standard practice in drug development.

Who can join: the full rules

Show full inclusion / exclusion criteria
Major Inclusion Criteria:

1. Is available for the entire duration of the study and follow up.
2. Is willing and able to comply with all study assessments and adhere to the protocol schedule and restrictions.
3. Voluntarily consents to participation in the trial as documented by signing the study informed consent form (ICF).
4. Has a body mass index (BMI) within 18 to 32 kg/m2, inclusive, and weighs ≥45 kg.
5. Is in good physical and mental health in the opinion of the Investigator or delegate.

Major Exclusion Criteria:

1. Has a history of severe allergic or anaphylactic reaction as determined by the Investigator or delegate.
2. Is pregnant, nursing, or is planning to become pregnant or breastfeed during the trial.
3. Has a known immunodeficiency disorder.
4. Has a history of malignancy other than non-melanoma skin cancer.
5. Has a history of human immunodeficiency virus (HIV) or positive serology for HIV at Screening.
6. Has positive laboratory evidence for active hepatitis at screening.
7. Has received a live vaccine within 2 months of Screening.
8. Has any other condition or prior therapy that, in the opinion of the Investigator or delegate, may potentially compromise the safety or compliance of the participant, or may preclude the participant from successfully completing the study.

Other inclusion/exclusion eligibility criteria apply.

Where it's running

  • CMAX Clinical Research
    Adelaide, South Australia, Australia
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.